Active, not recruitingPhase 4NCT05232929
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
Studying Spinal Muscular Atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genentech, Inc.
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Risdiplam(drug)
- Enrollment
- 403 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2026
Study locations (20)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Loma Linda University Health Care, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- University California - Irvine, Orange, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- University of Colorado, Aurora, Colorado, United States
- Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Nemour's Children's Hospital, Florida, Orlando, Florida, United States
- All Children's Research Institute, Inc., St. Petersburg, Florida, United States
- Advent Health Orlando, Winter Park, Florida, United States
- Rare Disease Research, LLC, Atlanta, Georgia, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05232929 on ClinicalTrials.govOther trials for Spinal Muscular Atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488338HABIT-ILE + FST in Children With SMA: Preliminary EffectivenessTeachers College, Columbia University
- RECRUITINGNCT07400198Gait and Bone Health in SMAJacqueline Montes
- RECRUITINGPHASE1, PHASE2NCT07070999Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Gemma Biotherapeutics
- RECRUITINGNANCT07321977Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic VolunteersInstitut de Myologie, France
- RECRUITINGPHASE2NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophyargenx
- RECRUITINGNANCT07286565Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn ScreeningCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT06532474Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed TherapiesSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT07265232Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).Lantu Biopharma